

## Expansion of Life Science Rare Disease Manufacturing Capabilities

Alexion is a biopharmaceutical company which was acquired by AstraZeneca in 2021, the company is now the Rare Disease Unit of AstraZeneca. The Alexion Athlone facility is based in Athlone, Co. Roscommon. The facility itself is located in Monksland Industrial Estate. The facility produces medicines for patients with life treating rare diseases . The Athlone facility is key to the Global Alexion network with 80% of all Alexion product being filled at our Fill Finish facility. Alexion's future manufacturing master plan for Ireland is aligned with Governments 'White Paper on Enterprise' that highlights the important of Life Science under section 3.3. <https://enterprise.gov.ie/en/publications/publication-files/white-paper-on-enterprise-2022-2030.pdf>

The facility currently employs approx. 400 personnel and has the following areas of manufacturing capabilities:

- Clinical & commercial drug substance operations.
- The filling of commercial and clinical operations.
- Technical Services
- Quality Assurance
- Quality Control
- Information Technology
- Engineering & Facilities

Alexion requests the Local Authorities consider the future development of the Monksland Pharma Hub as part of the Athlone Joint Plan and takes into account the zoned land requirements to future proof the area for growth from the existing companies in the area and potential further investment.

Alexion are committed to working with local authorities, the IDA and all relevant public and private stakeholders. Alexion is very engaged with the local communities and supports these communities through their Corporate and Social Responsibility programmes.

Regards,  
Michael Bartley  
Associate Director Engineering  
Alexion Athlone